Marker Therapeutics Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
Marker Therapeutics has a total shareholder equity of $9.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $11.7M and $2.0M respectively.
Belangrijke informatie
0%
Verhouding schuld/eigen vermogen
US$0
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$7.80m |
| Aandelen | US$9.70m |
| Totaal verplichtingen | US$1.97m |
| Totaal activa | US$11.68m |
Recente financiële gezondheidsupdates
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely
Oct 04
Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky
Jun 17Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely
Mar 04Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
Nov 19Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
Aug 17Recent updates
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely
Oct 04Marker Therapeutics awarded $2M FDA grant for leukemia candidate
Sep 13Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M
Aug 11Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky
Jun 17Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely
Mar 04Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
Nov 19Marker Therapeutics: Passing Through A Catalyst Desert
Oct 22Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
Aug 17Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
May 04Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?
Feb 22Marker shares rise as it completes construction of its cGMP manufacturing facility
Jan 13FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy
Jan 05Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?
Dec 29Marker Therapeutics EPS misses by $0.02
Nov 09Analyse van de financiële positie
Kortlopende schulden: MRKR's short term assets ($11.7M) exceed its short term liabilities ($2.0M).
Langlopende schulden: MRKR has no long term liabilities.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: MRKR is debt free.
Schuld verminderen: MRKR had no debt 5 years ago.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: MRKR has less than a year of cash runway based on its current free cash flow.
Voorspelling contante baan: MRKR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 4.2% each year